Home›Trial›NCT03997383
NCT03997383Phase 3ACTIVE NOT RECRUITING

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Study Summary

The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.

Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions / Drugs
PlaceboPatisiran
View on ClinicalTrials.gov ↗
Sponsor
ALNY
Alnylam Pharmaceuticals
RNAi Therapeutics
F27/100
Study Details
Enrollment360 participants
Primary Completion—
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219351+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 360 participants
Sponsor Catalyst Profile

Alnylam Pharmaceuticals (ALNY) is the sponsoring company for this trial. BiotechSign currently grades this company F (27/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ALNY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.